| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10012825 | HBV | ENSG00000134201.12 | protein_coding | GSTM5 | No | No | 2949 | P46439 Q5T8R2 |
| TVIS10033177 | HBV | ENSG00000134201.12 | protein_coding | GSTM5 | No | No | 2949 | P46439 Q5T8R2 |
| TVIS10040859 | HBV | ENSG00000134201.12 | protein_coding | GSTM5 | No | No | 2949 | P46439 Q5T8R2 |
| TVIS30084691 | HIV | ENSG00000134201.12 | protein_coding | GSTM5 | No | No | 2949 | P46439 Q5T8R2 |
| TVIS20016911 | HPV | ENSG00000134201.12 | protein_coding | GSTM5 | No | No | 2949 | P46439 Q5T8R2 |
| TVIS20039950 | HPV | ENSG00000134201.12 | protein_coding | GSTM5 | No | No | 2949 | P46439 Q5T8R2 |
| TVIS20040288 | HPV | ENSG00000134201.12 | protein_coding | GSTM5 | No | No | 2949 | P46439 Q5T8R2 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | GSTM5 |
|---|---|
| DrugBank ID | DB00143 |
| Drug Name | Glutathione |
| Target ID | BE0002285 |
| UniProt ID | P46439 |
| Regulation Type | |
| PubMed IDs | 17139284; 17016423; 11173863; 11684093 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Schnakenberg E, Breuer R, Werdin R, Dreikorn K, Schloot W: Susceptibility genes: GSTM1 and GSTM3 as genetic risk factors in bladder cancer. Cytogenet Cell Genet. 2000;91(1-4):234-8.@@Rao AV, Shaha C: Multiple glutathione S-transferase isoforms are present on male germ cell plasma membrane. FEBS Lett. 2001 Oct 26;507(2):174-80. |
| Groups | Approved; Investigational; Nutraceutical |
| Direct Classification | Peptides |
| SMILES | N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O |
| Pathways | Arachidonic Acid Metabolism; Flurbiprofen Action Pathway; 4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency; Oxaprozin Action Pathway; Rofecoxib Action Pathway; Pyruvate Kinase Deficiency; Acetaminophen Metabolism Pathway; Mefenamic Acid Action Pathway; Bromfenac Action Pathway; 5-Oxoprolinuria; gamma-Glutamyltransferase Deficiency; Naproxen Action Pathway; Sulindac Action Pathway; Glutathione Synthetase Deficiency; Piroxicam Action Pathway; Nabumetone Action Pathway; 2-Hydroxyglutric Aciduria (D and L Form); Meloxicam Action Pathway; Cyclophosphamide Action Pathway; Succinic Semialdehyde Dehydrogenase Deficiency; Valdecoxib Action Pathway; Ketorolac Action Pathway; 5-Oxoprolinase Deficiency; Acetylsalicylic Acid Action Pathway; Antipyrine Action Pathway; Glutathione Metabolism; Diclofenac Action Pathway; Homocarnosinosis; Cyclophosphamide Metabolism Pathway; Nepafenac Action Pathway |
| PharmGKB | PA449780 |
| ChEMBL | CHEMBL1543 |
